IP Library Granted Patent US 7,270,835
Granted Patent B2
US 7,270,835 · App. 10/689,856 · Granted Sep 18, 2007

Compositions that treat or inhibit pathological conditions associated with inflammatory response

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,270,835
App. No.
10/689,856
Granted
Sep 18, 2007
Kind
B2
Abstract

A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivatives or conjugates thereof.

Claims (11)

1. A method of preserving the health of joint tissues comprising administering to a patient, group consisting of oleanolic acid and ursolic acid, and a component selected from the group consisting of rosemary, an extract derived from rosemary, and a compound derived from rosemary.

2. The method according to claim 1 , wherein the dihydro-isohumulone has a structure according to Genus A having the formula:

wherein R′ is hydroxyl, and wherein R″ is CH 2 CH(CH 3 ) 2 .

3. A method of preserving the health of joint tissues comprising administering to a patient, group consisting of oleanolic acid and ursolic acid, and a component selected from the group consisting of rosemary, an extract derived from rosemary, and a compound derived from rosemary.

4. The method according to claim 3 , wherein the dihydro-isocohumulone has a structure according to Genus A having the formula:

wherein R′ is hydroxyl, and wherein R″ is CH(CH 3 ) 2 .

5. A method of preserving the health of joint tissues comprising administering to a patient, group consisting of oleanolic acid and ursolic acid, and a component selected from the group consisting of rosemary, an extract derived from rosemary, and a compound derived from rosemary.

6. The method according to claim 5 , wherein the dihydro-isoadhumulone has a structure according to Genus A having the formula:

wherein R′ is hydroxyl, and wherein R″ is CH(CH 3 )CH 2 CH 3 .

7. The method of claims 1 - 6 , wherein the compound derived from rosemary is selected from the group consisting of 1 ,8-cineole, 19-alpha-hydroxyursolic acid, 2-.beta.-hydroxyoleanolic acid, 3-O-acetyloleanolic acid, 3-O-acetylursolic acid, 6-methoxy-luteolin-7-glucoside, 6-methoxyluteolin, 6-methoxyluteolin-7-glucoside, methoxyluteolin-7-methylether, 7-ethoxy-rosmanol, 7-methoxy-rosmanol, alpha-amyrin, alpha-humulene, alpha-hydroxyhydrocatfeic acid, alpha-pinene, alpha-terpinene, alpha-terpinenyl acetate, alpha-terpineol, alpha-thujone, apigenin, apigenin-7-glucoside, curcumene, benzyl-alcohol, .beta.-amyrenone, .beta.-amyrin, beta.-elemene, .beta.-pinene, betulin, betulinic acid, bomeol, bornyl-acetate, caffeic acid, camphene, camphor, carnosic acid, cernosol, carvacrol, carvone, caryophyllene, caryophyllene-oxide, chiorogenic acid, diosmetin, gamma-terpinene, hesperidin, isoborneol, limonene, luteolin, luteolin-3′-O-(3″-O-acetyl)-.beta.-D-glucuronide, lutealin-3′-(4″-O-acctyl)-.beta.-D-glucuronidc. luteolin-3′-O-.beta.-D-- glucuronide, luteolin-7-glucoside, methyl-eugenol, inyrcene, neo-chlorogenlc acid, nepetin, octanoic acid, oleanolic acid, p-cymene, piperitenone, rosmanol, rosmaric acid, rosmaricine, rosmaridiphenol, rosemarinic acid, rosmarinol, rosmariquinone, sabinene, sabinyl acetate, salicylates, salicylic acid-2-.beta.-D-glucoside, squalene, tcrpinen-4-ol, terpinolene, thymol, trans-anethoic, trans-carveol, ursolic acid, verbenone, and zingiberene.

8. The method of claims 1 - 6 , wherein the composition further comprises glucosamine or chondroitin sulfate.

Assignments (9)
TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT - REEL/FRAME 057981/0156 Recorded Dec 24, 2025
From: FORTRESS CREDIT CORP.
To: METAGENICS LLC (FKA METAGENICS, INC.); METAPROTEOMICS, LLC
Reel/Frame 074057/0392 →
TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT - REEL/FRAME 058015/0602 Recorded Dec 23, 2025
From: FORTRESS CREDIT CORP.
To: METAGENICS LLC (FKA METAGENICS, INC.); METAPROTEOMICS, LLC
Reel/Frame 074050/0670 →
SECURITY INTEREST Recorded Nov 4, 2021
From: METAGENICS, INC.; METAPROTEOMICS, LLC
To: FORTRESS CREDIT CORP. (AS COLLATERAL AGENT)
Reel/Frame 058015/0602 →
SECURITY INTEREST Recorded Nov 1, 2021
From: METAGENICS, INC.; METAPROTEOMICS, LLC
To: FORTRESS CREDIT CORP., AS COLLATERAL AGENT
Reel/Frame 057981/0156 →
RELEASE OF SECURITY INTEREST Recorded Oct 25, 2021
From: BANK OF AMERICA, N.A.
To: META PROTEOMICS, LLC
Reel/Frame 057909/0199 →
RELEASE OF SECURITY INTEREST Recorded Oct 26, 2009
From: COMERICA BANK
To: METAGENICS, INC.; METAGENICS FAR EAST, INC.; META PROTEOMICS, LLC
Reel/Frame 023423/0951 →
SECURITY AGREEMENT Recorded Oct 15, 2009
From: META PROTEOMICS, LLC
To: BANK OF AMERICA, N.A.
Reel/Frame 023373/0684 →
SECURITY AGREEMENT Recorded Jun 2, 2006
From: METAGENICS, INC.; METAGENICS FAR EAST, INC.; META PROTEOMICS, L.L.C.
To: COMERICA BANK
Reel/Frame 017706/0815 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2004
From: TRIPP, MATTHEW L.; BABISH, JOHN G.; BLAND, JEFFREY S.; DARLAND, GARY K.; LERMAN, ROBERT; LUKACZER, DANIEL O.; LISKA, DEANN J.; HOWELL, TERRENCE
To: METAPROTEOMICS, LLC
Reel/Frame 014537/0978 →